Featured conditions Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Featured conditions
Cancer-related trials contact form
Phone: 855-776-0015 (toll-free)
International patient clinical studies questions
Tab Title Description
The purpose of this work is to develop brain cancer-specific small synthetic oligonucleotides (aptamers) that easily cross the BBB and capable of forming distinct three-dimensional configurations, enabling them to bind to target molecules with high affinity and specificity. The scope of this work is to develop brain cancer specific aptamers and combine them with patient-derived autologous T cells to enhance the tumor targeted immune reaction.
Our three major project aims are the creation of the Bispecific Aptamer T Cell Engagers (BATE) (aim 1), the creation of autologous T cell – BATE (aim 2), and finally the combination of our BATE and/or PATE with PDL-1 targeted CART cells (aim 3) for evaluation of synergism.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 10/15/2024. Questions regarding updates should be directed to the study team contact.
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
Mayo Clinic principal investigator
Abba Zubair, M.D., Ph.D.
Open for enrollment
Aleeshba Basil
Contact UsBasil.Aleeshba@mayo.edu